
Quarterly report 2025-Q3
added 11-04-2025
Masimo Corporation Revenue 2011-2026 | MASI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Masimo Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 B | 2.05 B | 2.04 B | 1.14 B | - | 938 M | 858 M | 790 M | 630 M | 587 M | - | 547 M | 493 M | 405 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 405 M | 1.05 B |
Quarterly Revenue Masimo Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 372 M | 371 M | 372 M | - | 343 M | 344 M | 340 M | - | 455 M | 565 M | 328 M | - | 565 M | 304 M | 295 M | 307 M | 305 M | 299 M | - | 278 M | 301 M | 270 M | 248 M | 229 M | 230 M | 232 M | 223 M | 211 M | 212 M | 213 M | 208 M | 193 M | 192 M | 197 M | 183 M | 168 M | 173 M | 171 M | 162 M | 153 M | 156 M | 155 M | - | 144 M | 141 M | 140 M | 142 M | 131 M | 137 M | 136 M | 132 M | 119 M | 123 M | 119 M | 112 M | 104 M | 110 M | 113 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 565 M | 104 M | 231 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AtriCure
ATRC
|
535 M | $ 29.85 | 1.05 % | $ 1.43 B | ||
|
AngioDynamics
ANGO
|
292 M | $ 10.6 | -1.03 % | $ 433 M | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Harvard Bioscience
HBIO
|
112 M | $ 0.47 | -4.15 % | $ 19.9 M | ||
|
Alcon
ALC
|
10.4 B | $ 77.32 | -1.5 % | $ 40.4 B | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
ICU Medical
ICUI
|
2.23 B | $ 125.85 | -2.28 % | $ 3.1 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
InfuSystem Holdings
INFU
|
110 M | $ 9.31 | -0.85 % | $ 192 M | ||
|
iRhythm Technologies
IRTC
|
747 M | $ 113.0 | -1.46 % | $ 3.62 B | ||
|
Intuitive Surgical
ISRG
|
10.1 B | $ 472.16 | -1.48 % | $ 169 B | ||
|
The Cooper Companies
COO
|
4.09 B | $ 69.92 | -2.24 % | $ 13.9 B | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 97.02 | -0.79 % | $ 4.7 B | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 159.36 | -0.17 % | $ 45.8 B | ||
|
Haemonetics Corporation
HAE
|
1.36 B | $ 59.92 | 0.72 % | $ 3.02 B | ||
|
electroCore
ECOR
|
16 M | $ 6.14 | -3.0 % | $ 33.9 K | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
Predictive Oncology
POAI
|
1.62 M | - | - | $ 31.1 M | ||
|
Ekso Bionics Holdings
EKSO
|
12.8 M | $ 11.56 | -2.12 % | $ 28 M | ||
|
Repro Med Systems
KRMD
|
41.1 M | $ 4.28 | -0.7 % | $ 198 M | ||
|
Baxter International
BAX
|
11.2 B | $ 17.4 | -3.36 % | $ 8.93 B | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 18.36 | 1.16 % | $ 846 M | ||
|
Nephros
NEPH
|
14.2 M | $ 3.5 | -7.89 % | $ 36.4 M | ||
|
ResMed
RMD
|
3.58 B | $ 230.84 | -0.68 % | $ 33.7 B | ||
|
Retractable Technologies
RVP
|
33 M | $ 0.71 | 2.62 % | $ 21.3 M | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
Merit Medical Systems
MMSI
|
1.52 B | $ 69.95 | 2.61 % | $ 4.14 B | ||
|
Envista Holdings Corporation
NVST
|
2.72 B | $ 24.61 | -3.26 % | $ 4.13 B | ||
|
STAAR Surgical Company
STAA
|
239 M | $ 18.84 | 2.45 % | $ 934 M | ||
|
Stereotaxis
STXS
|
32.4 M | $ 1.89 | 0.27 % | $ 172 M | ||
|
Teleflex Incorporated
TFX
|
569 M | $ 107.32 | -0.87 % | $ 4.79 B | ||
|
OraSure Technologies
OSUR
|
115 M | $ 2.97 | -3.88 % | $ 218 M | ||
|
LeMaitre Vascular
LMAT
|
250 M | $ 108.06 | 1.43 % | $ 2.45 B | ||
|
Utah Medical Products
UTMD
|
12.3 M | $ 63.28 | 1.02 % | $ 230 M | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 48.46 | 3.5 % | $ 159 M | ||
|
Microbot Medical
MBOT
|
117 K | $ 2.69 | -1.47 % | $ 27.4 M | ||
|
West Pharmaceutical Services
WST
|
3.07 B | $ 235.46 | 1.89 % | $ 17 B | ||
|
Repligen Corporation
RGEN
|
632 M | $ 114.2 | 0.39 % | $ 6.36 M | ||
|
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 11.54 | -2.2 % | $ 2.3 B | ||
|
Pulse Biosciences
PLSE
|
350 K | $ 21.57 | 1.27 % | $ 1.45 B | ||
|
STERIS plc
STE
|
5.46 B | $ 214.57 | 1.05 % | $ 21.2 B | ||
|
Milestone Scientific
MLSS
|
8.63 M | $ 0.28 | -3.75 % | $ 22.3 M |